Iovance Biotherapeutics
IOVA
219 hedge funds and large institutions have $3.67B invested in Iovance Biotherapeutics in 2020 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 73 increasing their positions, 70 reducing their positions, and 29 closing their positions.
453% more call options, than puts
Call options by funds: $112M | Put options by funds: $20.3M
79% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 29
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
10% more funds holding
Funds holding: 200 → 219 (+19)
7% more capital invested
Capital invested by funds: $3.44B → $3.67B (+$232M)
4% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 70
1.5% less ownership
Funds ownership: 98.38% → 96.88% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$59.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.6M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$17M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$15.8M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$69.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$41.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$37.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.3M |
IOVA Hedge Fund Activity: Q1 2020 in Review
219 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2020, worth a combined $3.67B — up 6.7% from $3.44B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new IOVA positions and 29 closed out — a net gain of 23 holders — while 73 added to existing stakes and 70 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $59.7M. The largest seller was Great Point Partners, cutting an estimated $69.6M.
- 219 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2020, up from 200 in Q4 2019.
- Funds reported $3.67B of Iovance Biotherapeutics stock for Q1 2020, up 6.7% quarter-over-quarter.
- 52 funds opened new Iovance Biotherapeutics positions in Q1 2020 and 29 closed out, a net change of +23 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2020 was Perceptive Advisors, an estimated $59.7M added.
- The largest Iovance Biotherapeutics seller in Q1 2020 was Great Point Partners, an estimated $69.6M sold.
Based on aggregated 13F filings for Q1 2020.